# Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease

> **NCT03318523** · PHASE2 · TERMINATED · sponsor: **Biogen** · enrollment: 357 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** Placebo
- **DRUG:** BIIB054

## Key facts

- **NCT ID:** NCT03318523
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-01-10
- **Primary completion:** 2020-10-26
- **Final completion:** 2021-04-29
- **Target enrollment:** 357 (ACTUAL)
- **Why stopped:** SPARK did not meet it's primary outcome measure for year 1 and failed to meet secondary outcome measures resulting in the development of BIIB054 (cinpanemab) for Parkinson's disease to be discontinued and SPARK study was closed.
- **Last updated:** 2022-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03318523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03318523, "Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03318523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*